Supporting Information for:

Amino-Borane Oligomers Bound to a Rh(I) Metal Fragment.

Romaeo Dallanegra, Adrian B. Chaplin, Jennifer Tsim and Andrew S. Weller*

Department of Chemistry, Inorganic Research Laboratory, University of Oxford, Oxford, OX1 3QR,

UK.

Experimental	S-2
Synthesis of new complexes	S-2
Selected NMR spectra	S-8
Dehydrocoupling	S-12
Crystallography	S-15
References	S-20

Experimental

All manipulations, unless otherwise stated, were performed under an atmosphere of argon, using standard Schlenk and glove-box techniques. Glassware was oven dried at 130°C overnight and flamed under vacuum prior to use. Pentane was dried using a Grubbs type solvent purification system (MBraun SPS-800) and degassed by successive freeze-pump-thaw cycles.¹ CD₂Cl₂, C₆H₅F and 1,2-C₆H₄F₂ were distilled under vacuum from CaH₂ and stored over 3 Å molecular sieves. H₃B·NMe₂BH₂·NMe₂H² and [H₂BNMeH]₃³ were made following literature procedures. H₃B·NMe₂H was purchased from Aldrich and sublimed before use (5 × 10⁻² Torr, 298 K). H₃B·NMeH₂⁴ and [Rh{P(C₅H₉)₂(η^2 -C₅H₇)}][BAr^F₄]⁵ were prepared as previously described. NMR spectra were recorded on Varian Unity 500 MHz or Varian Venus 300 MHz spectrometers at room temperature unless otherwise stated. In 1,2-C₆H₄F₂ and C₆H₅F, ¹H NMR spectra were referenced to the centre of the downfield solvent multiplet (δ = 7.07 and 7.11 respectively). ³¹P spectra were referenced against 85% H₃PO₄ (external). ¹¹B NMR spectra were referenced against BF₃·OEt₂ (external). Chemical shifts are quoted in ppm and coupling constants in Hz. ESI-MS were recorded on a Bruker MicrOTOF instrument. Microanalyses were performed by Elemental Microanalysis Ltd.

Synthesis of new complexes

Preparation of Rh(nbd){PiPr₂(C₅H₉)}Cl

This complex was prepared using the method of Chatt and Venanzi.⁶

¹H NMR (500 MHz, CDCl₃): δ 5.05 (s, 2H, HC=CH), 3.77 (s, 2H, nbd-CH₂), 3.75 (s, 2H, HC=CH), 2.20 - 1.37 (m, 13H, ⁱPr/Cyp), 1.29 (dd, 6H, *J*(PH) 13, *J*(HH) 7.3, ⁱPr-CH₃), 1.26 (dd, 6H, *J*(PH) 13, *J*(HH) 7.2, ⁱPr-CH₃).

³¹P {¹H} NMR (202 MHz, CDCI₃): δ 37.79 [d, *J*(RhP) 167].

Preparation of $[Rh{P^iPr_2(\eta^2-C_5H_7)}(\eta^6-C_6H_5F)][BAr^F_4]$

Rh(nbd){PiPr₂(C₅H₉)}Cl (58 mg, 0.138 mmol) and Na[BArF₄] (122 mg, 0.138 mmol) were dissolved in fluorobenzene (5 mL) and stirred for 20 hours. The reaction mixture was then filtered and the solvent was then removed *in vacuo* with the resulting solid being washed twice with pentane (2 x 3 mL). Diffusion of pentane into a fluorobenzene solution of the complex gave the product as yellow crystals. Yield 107 mg, 62 %. ¹H NMR (500 MHz, C₆H₅F): δ 8.35 (s, 8H, BAr^F₄), 7.66 (s, 4H, BAr^F₄), 6.14 – 6.03 (m, 4H, η⁶-C₆H₅F), 5.46 (m, 1H, η⁶-C₆H₅F), 3.91 (d, 2H, J(HH) 3, HC=CH), 1.53 (m, 2H, PiPr-CH, {³¹P δ 122.37}, sept, J(HH) 7), 1.44 (br, 1H, PCyp'-CH), 1.36 (apparent triplet, J = 13, 2H, PCyp'-CH₂), 1.18 (apparent ddt, 2H, J(PH) 48, J(HH) 13, J(HH) 3, PCyp'-CH₂), 0.85 (dd, 6H, J(PH) 7, J(HH) 4, PiPr-CH₃), 0.88 (dd, 6H, J(PH) 7, J(HH) 4, PiPr-CH₃)

³¹P {¹H} NMR (202 MHz, C₆H₅F): δ 122.37 [dd, *J*(RhP) 184, *J*(FP) 3].

ESI-MS (C₆H₅F, 60°C, 4.5kV) positive ion: m/z, 383.0775 [M]⁺ (calcd. 383.0806)

Anal. Calcd for C₄₉H₃₈B₁F₂₅P₁Rh₁ (1246.1460 gmol⁻¹): C, 47.22; H, 3.07. Found: C, 47.06; H, 3.04.

Preparation of $[Rh{P(C_5H_9)_2(\eta^2-C_5H_7)}(\eta^2:\eta^1-H_3B\cdot NMe_2BH_2\cdot NMe_2H)][BArF_4]$ (3a[BArF_4])

 $H_3B\cdot NMe_2BH_2\cdot NMe_2H$ (2.1 mg, 0.018 mmol, 1 eqv) was added to a solution of $[Rh\{P(C_5H_9)_2(\eta^2-C_5H_7)(C_6H_5F)\}][BAr^F_4]$ (24.0 mg, 0.018 mmol) in 1,2-C₆H₄F₂ (3 mL). Diffusion of pentane into the solution at -35°C gave **3a[BAr^F_4]** as pale yellow crystals which were stored at -35°C. Yield 12.5 mg, 51 %. At temperatures higher than 0°C solid **3a[BAr^F_4]** melts thus a satisfactory microanalysis could not be obtained.

¹**H NMR (500 MHz, 1,2-C₆H₄F₂):** δ 8.34 (s, 8H, BAr^F₄), 7.69 (s, 4H, BAr^F₄), 4.19 (bs, 1H, NH), 3.79 (s, 2H, HC=CH), 2.75 (d, 6H, *J*(HH) 5, NH-CH₃), 2.67 (s, 6H, N-CH₃), 2.08 – 1.44 (m, 21H, PCyp/Cyp'), 1.23 (br dd, 2H, *J*(PH) 47, *J*(HH) 14, PCyp'-CH₂), 0.10 (br, 3H, *J*(BH) 111, BH₃) -1.94 (br, 2H, *J*(BH) 117, BH₂).

¹H {¹¹B} NMR (500 MHz, 1,2-C₆H₄F₂): δ 0.10 (d, 3H, *J*(RhH) 21, BH₃), -1.94 (br, 2H, BH₂).

³¹P {¹H} NMR (202 MHz, 1,2-C₆H₄F₂): δ 114.58 [d, *J*(RhP) 170].

¹¹B NMR (160 MHz, 1,2-C₆H₄F₂): δ -4.33 (br).

ESI-MS (1,2-C₆H₄F₂, 60°C, 4.5kV) positive ion: m/z, 455.2420 [M]⁺ (calcd. 455.2406).

¹H NMR (500 MHz, CD₂Cl₂): δ 7.74 (s, 8H, BArF₄), 7.58 (s, 4H, BArF₄), 4.10 (bs, 1H, NH), 3.80 (s,

2H, HC=CH), 2.63 (d, 6H, J(HH) 5, NH-CH₃), 2.58 (s, 6H, N-CH₃), 2.23 – 1.50 (m, 21H,

PCyp/Cyp'), 1.34 (br dd, 2H, J(PH) 47, J(HH) 14, PCyp'-CH₂), -0.05 (br, 3H, J(BH) 111, BH₃), -2.10 (br, 2H, J(BH) 117, BH₂).

1**H {**11**B} NMR (500 MHz, CD₂Cl₂):** δ -0.06 (d, 3H, *J*(RhH) 21, BH₃), -2.10 (br, 2H, BH₂).

³¹P {¹H} NMR (202 MHz, CD₂Cl₂): δ 114.55 [d, *J*(RhP) 169].

¹¹B NMR (160 MHz, CD₂Cl₂): δ -4.32 (br)

¹H NMR (500 MHz, CD₂Cl₂, 200K): δ 7.74 (s, 8H, BAr^F₄), 7.57 (s, 4H, BAr^F₄), 4.20 (bs, 1H, NH), 3.68 (s, 2H, HC=CH), 2.56 (d, 6H, J(HH) 5, NH-CH₃), 2.54 (s, 6H, N-CH₃), 2.18 – 1.37 (m, 21H, PCyp/Cyp'), 1.26 (br dd, 2H, J(PH) 47, J(HH) 14, PCyp'-CH₂), -1.30 (br, 2H, BH₃), -2.32 (br, 2H, BH₂). The remaining B-H signal was not observed, presumably it was broad and/or obscured by the aliphatic signals.

¹H {¹¹B} NMR (500 MHz, CD₂Cl₂, 200K): δ -1.35 (v br, 2H, Rh<u>H</u>₂BH), -2.32 (br, 2H, BH₂)
 ³¹P {¹H} NMR (202 MHz, CD₂Cl₂, 200K): δ 113.11 [d, *J*(RhP) 169].
 ¹¹B NMR (160 MHz, CD₂Cl₂, 200K): δ very broad, no clear signals observed.

Preparation of $[Rh{P^{i}Pr_{2}(\eta^{2}-C_{5}H_{7})}(\eta^{2}:\eta^{1}-H_{3}B\cdot NMe_{2}BH_{2}\cdot NMe_{2}H)][BArF_{4}]$ (3b[BArF_{4}])

 $H_3B\cdot NMe_2BH_2\cdot NMe_2H$ (2.2 mg, 0.019 mmol, 1 eqv) was added to a solution of $[Rh{PiPr_2(\eta^2 - C_5H_7)}(C_6H_5F)][BArF_4]$ (24.0 mg, 0.019 mmol) in 1,2-C₆H₄F₂ (0.5 mL). Quantitative conversion to **3b[BArF_4]** was observed by NMR spectroscopy. Crystalline material was difficult to obtain however a single pale yellow crystal suitable for X-Ray diffraction was obtained from the diffusion of pentane into a 1,2-C₆H₄F₂ (3 mL) solution at -35°C.

¹H NMR (500 MHz, 1,2-C₆H₄F₂): δ 8.33 (s, 8H, BAr^F₄), 7.68 (s, 4H, BAr^F₄), 4.35 (bs, 1H, NH), 3.81 (s, 2H, HC=CH), 2.72 (d, 6H, *J*(HH) 5, NH-CH₃), 2.66 (s, 6H, N-CH₃), 1.93 (m, 2H, PiPr-CH), 1.83 (dd, 2H, *J*(HH) 14, *J*(PH) 13, PCyp'-CH₂), 1.78 (m, 1H, PCyp'-CH), 1.32 (apparent ddt, 2H, *J*(PH) 46, *J*(HH) 14, *J*(HH) 3, PCyp'-CH₂), 1.11 (dd, 6H, *J*(PH) 15, *J*(HH) 7, PiPr-CH₃), 1.07 (dd, 6H, *J*(PH) 15, *J*(HH) 7, PiPr-CH₃), 0.12 (br, 3H, *J*(BH) 110, BH₃) -2.14 (br, 2H, *J*(BH) 119, BH₂). ¹H {¹¹B} NMR (500 MHz, 1,2-C₆H₄F₂): δ 0.12 (d, 3H, *J*(RhH) 19, BH₃), -2.12 (br, 2H, BH₂). ³¹P {¹H} NMR (202 MHz, 1,2-C₆H₄F₂): δ 123.03 [d, *J*(RhP) 176].

¹¹**B NMR (160 MHz, 1,2-C₆H₄F₂):** δ -4.26 (br).

ESI-MS (1,2-C₆H₄F₂, 60°C, 4.5kV) positive ion: m/z, 403.2066 [M]⁺ (Calcd. 403.2092).

¹H NMR (500 MHz, CD₂Cl₂): δ 7.74 (s, 8H, BAr^F₄), 7.58 (s, 4H, BAr^F₄), 4.13 (bs, 1H, NH), 3.82 (s, 2H, HC=CH), 2.62 (d, 6H, J(HH) 6, NH-CH₃), 2.59 (br s, 6H, N-CH₃), 2.08 (m, 2H, PⁱPr-CH), 1.95 (br m, 1H, PCyp'-CH), 1.94 (dd, 2H, J(HH) 13, J(PH) 12, PCyp'-CH₂), 1.44 (apparent ddt, 2H, J(PH) 46, J(HH) 14, J(HH) 3, PCyp'-CH₂), 1.24 (dd, 6H, J(PH) 14, J(HH) 7, PⁱPr-CH₃), 1.18 (dd, 6H, J(PH) 14, J(HH) 7, PⁱPr-CH₃), -0.02 (br, 3H, J(BH) 110, BH₃), -2.26 (br, 2H, J(BH) 119, BH₂).
¹H {¹¹B} NMR (500 MHz, CD₂Cl₂): -0.03 (d, 3H, J(RhH) 21, BH₃), -2.25 (br, 2H, BH₂).

³¹P {¹H} NMR (202 MHz, CD₂Cl₂): δ 123.44 [d, *J*(RhP) 176].

¹¹**B NMR (160 MHz, CD₂Cl₂):** δ -4.29 (br).

¹H NMR (500 MHz, CD₂Cl₂, 200K): δ 7.74 (s, 8H, BAr^F₄), 7.56 (s, 4H, BAr^F₄), 4.25 (bs, 1H, NH),
3.70 (s, 2H, HC=CH), 2.58 – 2.53 (m, 12H, NH-CH₃, N-CH₃), 1.99 (m, 2H, PⁱPr-CH), 1.88 (br m,
1H, PCyp CH), 1.82 (dd, 2H, J(HH) 13, J(PH) 12, PCyp'-CH₂), 1.37 (br dd, 2H, J(PH) 46, J(HH) 13
PCyp'-CH₂), 1.14 (dd, 6H, J(PH) 14, J(HH) 7, PⁱPr-CH₃), 1.09 (dd, 6H, J(PH) 14, J(HH) 7, PⁱPr-CH₃), -1.34 (br, 2H, BH₃), -2.48 (br, 2H, BH₂). The remaining B-H signal was not observed,
presumably it was broad and/or obscured by the aliphatic signals.
¹H {¹¹B} NMR (500 MHz, CD₂Cl₂, 200K): -1.35 (v br, 2H, Rh<u>H</u>₂BH), -2.49 (br, 2H, BH₂).
³¹P {¹H} NMR (202 MHz, CD₂Cl₂, 200K): δ 121.59 [d, J(RhP) 172].

¹¹B NMR (160 MHz, CD₂Cl₂, 200K): δ very broad, no clear signals observed.

Preparation of $[Rh{P(C_5H_9)_2(\eta^2-C_5H_7)}(\eta^1:\eta^1:\eta^1-H_2BNMeH)_3][BArF_4]$ (4a $[BArF_4]$)

 $[H_2BNMeH]_3$ (3.5 mg, 0.027 mmol, 1.5 eqv) was added to a solution of $[Rh{P(C_5H_9)_2(\eta^2 - C_5H_7)}(C_6H_5F)][BArF_4]$ (24.0 mg, 0.018 mmol) in 1,2-C₆H₄F₂ (3 mL). The solution was stirred for 24 hours. Diffusion of pentane into the solution at 20°C gave **4a[BArF_4]** as pale yellow crystals. Yield 10.5 mg, 43 %.

¹**H NMR (500 MHz, 1,2-C₆H₄F₂):** δ 8.34 (s, 8H, BAr^F₄), 7.69 (s, 4H, BAr^F₄), 3.81 (s, 2H, HC=CH), 3.26 (br s, 3H, NH), 2.73 (d, *J*(HH) 5, 9H, N-CH₃), 2.17 – 1.44 (m, 21H, PCyp/Cyp'), 1.16 (apparent ddt, 2H, *J*(PH) 49, *J*(HH) 14, *J*(HH) 3, PCyp'-CH₂), -3.16 (br, 3H, Rh<u>H</u>BH). The RhHB<u>H</u> signal was not unequivocally identified, presumably it was broad and/or obscured by the aliphatic signals. **1H {11B} NMR (500 MHz, 1,2-C₆H₄F₂):** 2.63 (br d, 3H, *J* 9, RhHBH), -3.17 (br, 3H, RhHBH).

³¹P {¹H} NMR (202 MHz, 1,2-C₆H₄F₂): δ 113.07 [d, *J*(RhP) 161].

¹¹**B NMR (160 MHz, 1,2-C₆H₄F₂):** δ -5.34 (br).

ESI-MS (1,2-C₆H₄F₂, 60°C, 4.5kV) positive ion: m/z, 468.2497 [M]⁺ (calcd. 468.2533)

¹H NMR (500 MHz, CD₂Cl₂): δ 7.74 (s, 8H, BAr^F₄), 7.58 (s, 4H, BAr^F₄), 3.81 (s, 2H, HC=CH), 3.10 (bs, 3H, NH), 2.62 (d, *J*(HH) 5, 9H, N-CH₃), 2.37 – 1.42 (m, 21H, PCyp/Cyp'), 1.15 (apparent ddt, 2H, *J*(PH) 49, *J*(HH) 14, *J*(HH) 3, PCyp'-CH₂), -3.30 (br, 3H, Rh<u>H</u>BH). The RhHB<u>H</u> signal was not unequivocally identified, presumably it was broad and/or obscured by the aliphatic signals. ¹H {¹¹B} NMR (500 MHz, CD₂Cl₂): δ 2.40 (br d, 3H, *J* 10, RhHB<u>H</u>), -3.30 (br, 3H, Rh<u>H</u>BH). ³¹P {¹H} NMR (202 MHz, CD₂Cl₂): δ 112.61 [d, *J*(RhP) 161].

¹¹**B NMR (160 MHz, CD₂Cl₂):** δ -5.57 (br dd, *J*(BH) 117, 83).

¹H NMR (500 MHz, CD₂Cl₂, 200K): δ 7.73 (s, 8H, BAr^F₄), 7.55 (s, 4H, BAr^F₄), 3.69 (s, 2H, HC=CH), 3.19 (bs, 3H, NH), 2.57 (v br, 9H, N-CH₃), 2.24 – 1.30 (m, 21H, PCyp/Cyp'), 1.09 (br dd, 2H, *J*(PH) 49, *J*(HH) 14, PCyp'-CH₂), -1.08 (br, 2H, Rh<u>H</u>BH), -8.31 (br, 1H, Rh<u>H</u>BH). The remaining RhHB<u>H</u> signals were not unequivocally identified, presumably they are broad and/or obscured by the aliphatic signals.

¹H {¹¹B} NMR (500 MHz, CD₂Cl₂, 200K): δ -1.08 (br, 2H, Rh<u>H</u>BH), -8.31 (br, 1H, Rh<u>H</u>BH).

³¹P {¹H} NMR (202 MHz, CD₂Cl₂, 200K): δ 111.29 [d, *J*(RhP) 159].

¹¹B NMR (160 MHz, CD₂Cl₂, 200K): δ very broad, no clear signal observed.

Anal. Calcd for C₅₀H₅₅B₄F₂₄N₃P₁Rh₁.C₆H₄F₂ (1445.170 gmol⁻¹): C, 46.54; H, 4.11; N, 2.91. Found: C, 46.16; H, 4.05; N, 2.81.

Preparation of [Rh{PⁱPr₂(η^2 -C₅H₇)}(η^1 : η^1 : η^1 -H₂BNMeH)₃][BArF₄] (4b[BArF₄])

 $[H_2BNMeH]_3$ (3.5 mg, 0.027 mmol, 1.5 eqv) was added to a solution of $[Rh{PiPr_2(\eta^2-C_5H_7)}(C_6H_5F)][BArF_4]$ (24.0 mg, 0.019 mmol) in 1,2-C₆H₄F₂ (3 mL). The solution was stirred for 24 hours. Quantitative conversion to **4b[BArF_4]** was observed by NMR spectroscopy from *in situ* generated samples. Crystalline material was difficult to obtain however a single pale yellow crystal suitable for X-Ray diffraction was obtained from the diffusion of pentane into a 1,2-C₆H₄F₂ (3 mL) solution at -35°C.

¹H NMR (500 MHz, 1,2-C₆H₄F₂): δ 8.33 (s, 8H, BAr^F₄), 7.68 (s, 4H, BAr^F₄), 3.81 (s, 2H, HC=CH), 3.31 (br s, 3H, NH), 2.71 (d, *J*(HH) 6, 9H, N-CH₃), 1.98 (m, 2H, PⁱPr-CH), 1.81 (br m, 1H, PCyp²-CH), 1.76 (virtual triplet, 2H, *J*(HH) ~ *J*(PH) 13, PCyp²-CH₂), 1.34 – 1.15 (m, 12H, PⁱPr-CH₃) 1.26 – 1.05 (partially obscured multiplet, 2H, PCyp²-CH₂), -3.32 (collapsed quartet, 3H, *J*(BH) 87, Rh<u>H</u>BH). The remaining RhHB<u>H</u> signal was not unequivocally identified, presumably it is broad and/or obscured by the aliphatic signals.

¹H {¹¹B} NMR (500 MHz, 1,2-C₆H₄F₂): δ 2.62 (br d, 3H, J 10, RhHB<u>H</u>), -3.32 (br, 3H, Rh<u>H</u>BH).

³¹P {¹H} NMR (202 MHz, 1,2-C₆H₄F₂): δ 120.7 [d, J(RhP) 165].

¹¹**B NMR (160 MHz, 1,2-C₆H₄F₂):** δ -5.24 (br dd, $\mathcal{J}(BH)$ 118, 87).

ESI-MS (1,2-C₆H₄F₂, 60°C, 4.5kV) positive ion: m/z, 416.2230 [M]+ (calcd. 416.2218)

¹**H NMR (500 MHz, CD₂Cl₂):** δ 7.73 (s, 8H, BAr^F₄), 7.58 (s, 4H, BAr^F₄), 3.85 (s, 2H, HC=CH), 3.18 (bs, 3H, NH), 2.62 (d, *J*(HH) 5, 9H, N-CH₃), 2.08 (m, 2H, PⁱPr-CH), 1.97 (br m, 1H, PCyp'-CH), 1.82 (virtual triplet, 2H, *J*(HH) ~ *J*(PH) 13, PCyp'-CH₂), 1.34 -1.19 (m, 12H, PⁱPr-CH₃), 1.28 – 1.08 (partially obscured multiplet, 2H, PCyp'-CH₂), -3.44 (collapsed quartet, 3H, *J*(BH) 87, Rh<u>H</u>BH). The remaining RhHB<u>H</u> signal was not unequivocally identified, presumably it is broad and/or obscured by the aliphatic signals.

¹H {¹¹B} NMR (500 MHz, CD₂Cl₂): δ 2.40 (br d, 3H, *J* 9, RhHB<u>H</u>), -3.43 (br, 3H, Rh<u>H</u>BH).

³¹**P** {¹**H**} **NMR (202 MHz, CD₂Cl₂):** δ 120.70 [d, *J*(RhP) 163].

¹¹**B NMR (160 MHz, CD₂Cl₂):** δ -5.45 (dd, *J*(HH) 118, 87).

¹H NMR (500 MHz, CD₂Cl₂, 200K): δ 7.73 (s, 8H, BAr^F₄), 7.55 (s, 4H, BAr^F₄), 3.73 (s, 2H, HC=CH), 3.20 (bs, 3H, NH), 2.56 (v br, 9H, N-CH₃), 2.00 (m, 2H, PⁱPr-CH), 1.90 (br m, 1H, PCyp²-CH), 1.70 (virtual triplet, 2H, J(HH) ~ J(PH) 13, PCyp²-CH₂), 1.16 (dd, 12H, J(HH) 7, J(PH) 14, PⁱPr-CH₃) 1.23 – 0.97 (partially obscured multiplet, 2H, PCyp²-CH₂), -1.11 (br, 2H, Rh<u>H</u>BH), -8.80 (v br, 1H, Rh<u>H</u>BH). The remaining RhHB<u>H</u> signals were not unequivocally identified, presumably they are broad and/or obscured by the aliphatic signals.

¹H {¹¹B} NMR (500 MHz, CD₂Cl₂, 200K): δ -1.11 (br, 2H, Rh<u>H</u>BH), -8.85 (br, 1H, Rh<u>H</u>BH). ³¹P {¹H} NMR (202 MHz, CD₂Cl₂, 200K): δ 119.33 [d, *J*(RhP) 162].

¹¹B NMR (160 MHz, CD₂Cl₂, 200K): δ very broad, no clear signal observed.

Selected NMR spectra

* = free oligomer resonances

= new BH resonance as a result of performing ¹H {¹¹B} NMR spectroscopy experiment







Figure S2: ¹H NMR (CD₂Cl₂) spectra of **3b[BArF₄]** at room temperature (top) and 200K (bottom).



Figure S3: ¹H NMR (CD₂Cl₂) spectra of 4a[BArF₄] at room temperature (top) and 200K (bottom).



Figure S4: ¹H NMR (CD₂Cl₂) spectra of 4b[BArF₄] at room temperature (top) and 200K (bottom).



Figure S5: ¹¹B NMR spectra of the catalytic dehydrocoupling of H₃B·NMe₂H with **3a[BArF₄]** (20 mol %, 1,2-C₆H₄F₂). a = **3a**, b = H₃B·NMe₂BH₂·NMe₂H, c = H₃B·NMe₂H, d = (μ -NMe₂)B₂H₅, e = H₂BNMe₂, f = [H₂BNMe₂]₂, * = [BArF₄]⁻.



Figure S6: ¹¹B NMR spectra of the catalytic dehydrocoupling of $H_3B \cdot NMe_2BH_2 \cdot NMe_2H$ with **3a[BArF_4]** (20 mol % relative to $H_3B \cdot NMe_2H$, 1,2-C₆H₄F₂). a = **3a**, b = H₃BNMe₂BH₂NMe₂H, d = (µ-NMe₂)B₂H₅, f = [H₂BNMe₂]₂, g = (NMe₂)₂BH, * = [BArF₄]⁻.



Figure S7: left: ¹¹B NMR spectra of the catalytic dehydrocoupling of $H_3B \cdot NMeH_2$ with $4a[BArF_4]$ (20 mol %, 1,2-C₆H₄F₂). Right: ¹¹B NMR spectrum of the catalytic dehydrocoupling of [H₂BNMeH]₃ with $4a[BArF_4]$ (20 mol % relative to $H_3B \cdot NMeH_2$, 1,2-C₆H₄F₂). h = 4a, i = [H₂BNMeH]₃, j = H₃B \cdot NMeH₂, k = [HBNMe]₃, * = [BArF₄]⁻. Partial solubility of i and j makes reliable ratios based upon relative intergrals difficult to obtain.

Crystallography

Data was acquired on a Nonius Kappa CCD diffractometer using graphite monochromated Mo K α radiation ($\lambda = 0.71073$ Å) and a low-temperature device (150 K);⁷ data was collected using COLLECT, reduction and cell refinement was performed using DENZO/SCALEPACK.⁸ Structures were solved by direct methods using SIR2004⁹ and refined full-matrix least squares on F² using SHELXL-97.⁸ All nonhydrogen atoms were refined anisotropically. The alkene and B-H hydrogen atoms were located on the difference map; their isotropic displacement parameters were fixed to ride on the parent atoms. The B-H hydrogen atoms were freely refined; restraints were applied to the alkene C-H distances. All other hydrogen atoms were placed in calculated positions using the riding model. Disorder of the fluorobenzene ligand in [Rh{PiPr₂(η^2 -C₅H₇)}(η^6 -C₆H₅F)][BAr^F₄] was treated by modelling the fluorine atom over two sites and restraining the 1,2 and 1,3-C-F distances. Disorder in the phosphine ligands (present in all structures) was treated by modelling the appropriate phosphine substituents over two sites and restraining their geometry. Disorder of the pentane solvent model in 4b[BArF₄] was treated by modelling it over two sites and restraining its geometry (the central atom lies on a special position). Problematic solvent disorder in **3b**[**BAr**^F₄] was treated using the SQUEEZE algorithm.¹⁰ Rotational disorder of the anion CF₃ groups was treated by modelling the fluorine atoms or the entire CF₃ group over two sites and restraining their geometry. Restraints to thermal parameters were applied where necessary in order to maintain sensible values. Graphical representations were made with ORTEP3.¹¹

Supplementary Material (ESI) for Chemical Communications This journal is (c) The Royal Society of Chemistry 2010

	$[Rh\{PiPr_2(\eta^2-C_5H_7)\}(\eta^6-C_6H_5F)][BAr^{F}_4]$	3a[BArF ₄]	4a[BAr ^F 4]
Formula	C ₄₉ H ₃₈ BF ₂₅ PRh	C ₄₇ H ₅₁ B ₃ F ₂₄ N ₂ PRh	C ₄₆ H ₅₁ B ₄ F ₂₄ N ₃ PRh·½(C ₅ H ₁₂)
Μ	1246.48	1266.21	1315.09
cryst syst	Orthorhombic	Triclinic	Monoclinic
space group	<i>P</i> 2 ₁ 2 ₁ 2 ₁	<i>P</i> -1	P2 ₁ /c
<i>a</i> [Å]	12.51030(10)	13.11340(10)	13.22060(10)
b [Å]	19.3211(2)	15.09320(10)	18.33470(10)
<i>C</i> [Å]	20.3470(3)	15.6507(2)	24.0722(2)
α [deg]		84.6142(4)	
β [deg]		78.4318(4)	98.7365(4)
γ [deq]		86.9282(4)	
V[ų]	4918.13(10)	3019.40(5)	5767.30(7)
Z	4	2	4
density [gcm-3]	1.683	1.393	1.515
μ (mm ⁻¹)	0.511	0.415	0.438
θ range [deg]	$5.10 \le \theta \le 26.37$	$5.10 \le \theta \le 26.37$	$5.14 \le \theta \le 26.37$
Refins collected	9979 [<i>R</i> _{int} = 0.078]	23676 [<i>R</i> _{int} = 0.0154]	22949 [<i>R</i> _{int} = 0.0231]
Completeness	99.0 %	99.2 %	99.2 %
no. of data/restr/param	9979 / 409 / 805	12244 / 982 / 962	11699 / 590 / 930
<i>R</i> 1 [<i>I</i> > 2 <i>o</i> (<i>I</i>)]	0.0406	0.0466	0.0415
wR2 [all data]	0.0986	0.1364	0.1143
GoF	1.023	1.082	1.041
Flack x	-0.03(2)		
Largest diff. pk and hole [eÅ ⁻³]	0.683, -0.503	0.744, -0.855	0.699, -0.619

 Table 1: Crystallographic data.



Figure S8: Solid-state structure of $[Rh{PiPr_2(\eta^2-C_5H_7)}(\eta^6-C_6H_5F)][BArF_4]$; ellipsoids are depicted at the 50% probability level. Anion and minor disordered components omitted for clarity. Selected bond lengths (Å): Rh1-P1, 2.2507(11); Rh1-C_{arener}, 2.259(4)-2.324(4); Rh1-C9, 2.127(5); Rh1-C10, 2.131(5).

Supplementary Material (ESI) for Chemical Communications This journal is (c) The Royal Society of Chemistry 2010



Figure S9: Solid-state structure of **3b[BAr**^F₄]; ellipsoids are depicted at the 50% probability level. Anion and minor disordered components omitted for clarity. Selected bond lengths (Å) and angles (°): Rh1-P1, 2.2058(9), Rh1-B1, 2.242(5); Rh1-B2, 2.626(4); Rh1-H1A, 1.85(5), Rh1-H1B, 1.84(5), Rh1-H2A, 1.96(4); Rh1-C7, 2.107(4); Rh1-C8, 2.121(4); B1-H1A, 1.23(5); B1-H1B, 1.22(5); B1-H1C, 1.13(5); B2-H2A, 1.13(4); B2-H2B, 1.12(4); B1-N1-B2, 103.3(3); N1-B2-N2, 112.7(3); Rh1-H2A-B2, 113(3).



Figure S10: Solid-state structure of **4b[BAr**^F₄]; ellipsoids are depicted at the 50% probability level. Anion and minor disordered components omitted for clarity. Selected bond lengths (Å) and angles (°): Rh1-P1, 2.2354(8); Rh1-B1, 2.693(4); Rh1-B2, 2.808(4); Rh1-B3, 2.761(4); Rh1-H1A, 1.84(4); Rh1-H2A, 1.94(4); Rh1-H3A, 1.86(4); Rh1-C6, 2.096(3); Rh1-C7, 2.094(3); B1-H1A, 1.20(4); B1-H1B, 1.06(4); B2-H2A, 1.17(4); B2-H2B, 1.10(4), B3-H3A, 1.20(4); B3-H3B, 1.12(4); B1-N2-B2, 112.9(3); B2-N1-B3, 111.7(3); B3-N3-B1, 112.6(3); Rh1-H1A-B1, 123(3); Rh1-H2A-B2, 128(3); Rh1-H3A-B3, 128(3).

References

- ¹ A. B. Pangborn, M. A. Giardello, R. H. Grubbs, R. K. Rosen, F. J. Timmers, *Organometallics* **1996**, *15*, 1518.
- ² C. A. Jaska; *I.* Manners, *J. Am. Chem. Soc.*, **2004**, *126*, 9776.
- ³ C. K. Narula, J. F. Janik, E. N. Duesler, R. T. Paine, R. Schaeffer, *Inorg. Chem.*, **1986**, *25*, 3346.
- ⁴ S. Aldridge, A.J. Downs, C.Y. Tang, S. Parsons, M.C. Clarke, R. D. L. Johnstone, H. E. Robertson, D. W. H. Rankin, D. A. Wann, *J. Am. Chem. Soc.* **2009**, *131*, 2231.
- T. M. Douglas, S. K. Brayshaw, R. Dallanegra, S. A. Macgregor, G. L. Moxham, G. Kociok-Köhn,
 P. Vadivelu, A. S. Weller, T. Wondimagegn, *Chem. Eur. J.* 2008, *14*, 1004.
- ⁶ J. Chatt, L. M. Venanzi, *J. Chem. Soc.*, **1957**, 4735.
- ⁷ J. Cosier, A. M. Glazer, *J. Appl. Cryst.*,**1986**, *19*, 105.
- Z. Otwinowski, Z. Minor, Processing of X-ray Diffraction Data Collected in Oscillation Mode, Methods Enzymol. 1997, 276, Eds C. W. Carter, R. M. Sweet, Academic Press.
- ⁹ M. C. Burla, R. Caliandro, M. Camalli, B. Carrozzini, G. L. Cascarano, L. De Caro, C. Giacovazzo, G. Polidori, R. Spagna, *J. Appl. Cryst.* 2005, *38*, 381.
- (a) A. L. Spek, PLATON, A Multipurpose Crystallographic Tool, Utrecht University: The Netherlands, 2007. (b) A. L. Spek, *J. Appl. Cryst.* 2003, *36*, 7.
- ¹¹ L. J. Farrugia, *J. Appl. Cryst.* **1997**, 30, 565.